Research

Hormonal

Weekly subcutaneous semaglutide (titrated to 2.0 mg) significantly reduces body weight in clozapine-treated patients with schizophrenia and obesity compared to placebo over 36 weeks.

This protocol outlines a clinical trial for using semaglutide to treat obesity in people with schizophrenia taking clozapine. It is not a general recommendation but a research study. If you are interested, consult your psychiatrist about eligibility for clinical trials, as this specific intervention is currently under investigation for this population.

WeakSupportsVERY_LOW confidence
Based on preclinical research on the impact of antipsychotics on the GLP-1 pathway, it is expected that add-on therapy with semaglutide once a week in clozapine-treated patients diagnosed with schizophrenia spectrum disorder will result in significantly greater weight loss as a proportion of body weight at endpoint compared with placebo.
Dan Siskind et al. · BJPsych Open · 2023

Why this rating

This is a study protocol; no results are reported, only the hypothesis and design.

Source

Effects of semaglutide on body weight in clozapine-treated people with schizophrenia and obesity: study protocol for a placebo-controlled, randomised multicentre trial (COaST)

Dan Siskind et al. · BJPsych Open · 2023

DOI 10.1192/bjo.2023.532

rct · n=80Cited 8×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →